Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2-positive Metastatic Breast Cancer Clear all
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin, Trastuzumab deruxtecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
33
States / cities
Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions
Onapristone, Fulvestrant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastases, Brain
Interventions
capecitabine, lapatinib, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
17
States / cities
Goodyear, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
223
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
561
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 357 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 1:08 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
NERATINIB, FULVESTRANT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
62
States / cities
Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
RLY-2608, Capivasertib, Fulvestrant
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
51
States / cities
Gilbert, Arizona • Beverly Hills, California • Duarte, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
Interventions
PRS-343 in Combination with Atezolizumab
Drug
Lead sponsor
Pieris Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Gilbert, Arizona • Burbank, California • Corona, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Intra-arterial Cerebral Infusion of Trastuzumab
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
MEN1611, Trastuzumab, Fulvestrant
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Farmington Hills, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
HER-2 Positive Metastatic Breast Cancer
Interventions
Etoposide, Trastuzumab
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Trastuzumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
Niraparib, Trastuzumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 22, 2026, 1:08 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
70
States / cities
Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
BGB-21447, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Iowa City, Iowa • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced May 22, 2026, 1:08 AM EDT